Titre :
  • Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Auteur : Strumberg, Dirk ; Richly, Heike ; Hilger, Ralf A ; Schleucher, Norbert ; Korfee, Sonke ; Tewes, Mitra ; Faghih, Markus ; Brendel, Erich ; Voliotis, Dimitris ; Haase, Claus G ; Schwartz, Brian ; Awada, Ahmad ; Voigtmann, Rudolf ; Scheulen, M E ; Seeber, Siegfried
Informations sur la publication : Journal of clinical oncology, 23, 5, (page 965-972)
Statut de publication : Publié, 2005-02
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adolescent
Adult
Aged
Antineoplastic Agents -- administration & dosage
Antineoplastic Agents -- adverse effects
Antineoplastic Agents -- pharmacokinetics
Benzenesulfonates -- administration & dosage
Benzenesulfonates -- pharmacokinetics
Carcinoma, Hepatocellular -- drug therapy
Cohort Studies
Colonic Neoplasms -- drug therapy
Diarrhea -- chemically induced
Extracellular Signal-Regulated MAP Kinases -- drug effects
Fatigue -- chemically induced
Female
Humans
Liver Neoplasms -- drug therapy
Lymphocytes -- drug effects
Lymphocytes -- enzymology
Male
Middle Aged
Phosphatidylethanolamine Binding Protein -- administration & dosage
Phosphatidylethanolamine Binding Protein -- adverse effects
Phosphatidylethanolamine Binding Protein -- pharmacokinetics
Phosphorylation -- drug effects
Protein Kinase Inhibitors -- administration & dosage
Protein Kinase Inhibitors -- adverse effects
Protein Kinase Inhibitors -- pharmacokinetics
Pyridines -- administration & dosage
Pyridines -- pharmacokinetics
Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
Rectal Neoplasms -- drug therapy
Safety
Note : Clinical Trial
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0732-183X 
info:doi/10.1200/JCO.2005.06.124
info:pii/JCO.2005.06.124
info:pmid/15613696